Bellevue Life Sciences Acquisition Corp. Rights
BLACR
BLACR was delisted on the 14th of February, 2025.
28 hedge funds and large institutions have $681K invested in Bellevue Life Sciences Acquisition Corp. Rights in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 2 closing their positions.
24% more capital invested
Capital invested by funds: $550K → $681K (+$131K)
0% more funds holding
Funds holding: 28 → 28 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$56K |
| 2 |
Walleye Trading
New York
|
+$17.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$13 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$17.8K |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$17.4K |
| 3 |
SIA
Schechter Investment Advisors
Birmingham,
Michigan
|
-$3.76K |
| 4 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
-$1.61K |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$389 |
BLACR Hedge Fund Activity: Q4 2024 in Review
28 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Bellevue Life Sciences Acquisition Corp. Rights (BLACR) for Q4 2024, worth a combined $681K — up 24% from $550K a quarter earlier.
Fund positioning in BLACR was balanced in Q4 2024: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 7 trimmed.
The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $56K. The largest seller was Walleye Capital, cutting an estimated $17.8K.
- 28 institutional investors held Bellevue Life Sciences Acquisition Corp. Rights (BLACR) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $681K of Bellevue Life Sciences Acquisition Corp. Rights stock for Q4 2024, up 24% quarter-over-quarter.
- 2 funds opened new Bellevue Life Sciences Acquisition Corp. Rights positions in Q4 2024 and 2 closed out, a net change of 0 holders.
- The largest Bellevue Life Sciences Acquisition Corp. Rights buyer in Q4 2024 was Toronto Dominion Bank, an estimated $56K added.
- The largest Bellevue Life Sciences Acquisition Corp. Rights seller in Q4 2024 was Walleye Capital, an estimated $17.8K sold.
Based on aggregated 13F filings for Q4 2024.